SmallCapReview.com - Microcap Stocks to Watch - ACHN, GSS, TSYS

Salem, NC -- (SBWIRE) -- 11/04/2013 -- Achillion Pharmaceuticals (NASDAQ: ACHN) $2.53. Today announced a poster presentation detailing the preclinical profile of ACH-3422, a uridine-analog nucleotide prodrug being advanced for the potential treatment of chronic hepatitis C viral infection. The poster presentation details the potent and specific inhibition of HCV NS5B polymerase by ACH-3422, and the demonstrated low risk for mitochondrial toxicity based upon in vitro studies with human cells in static and proliferating conditions, and high efficiency in the conversion of ACH-3422 into the triphosphate within human hepatocyte cell lines.